Addendum
Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Report documents
-
Addendum
Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Additional information
Federal Joint Committee (G-BA)
19-05-2022 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- G22-13
- Commission
- Commission awarded on 12.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
Connected Projects
-
Dossier assessment
Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed